It acts as a gastric and pancreatic lipase inhibitor, reducing the absorption of dietary fat by preventing the lipase-catalyzed breakdown in the gastrointestinal tract, leading to weight loss ( Currently, naltrexone/bupropion and phentermine/topiramate are the only approved combination therapies, designed to synergistically target two distinct pathways to induce weight loss (32)
If the sublingual form proves to be as effective or even more convenient than injections, it could become a preferred choice for many patients
Room-temperature storage undermines all three of these pillars
Moreover, pollutions increase the sebum secretion rate, decrease the content of vitamin E in the skin, and promote inflammation, which worsens the skin condition
Signaling pathways activated by the growth hormone receptor
Slentrol (dirlotapide) is FDA-approved for canine weight loss in severe cases